Pacira Biosciences Inc. (PCRX)

43.34
0.01 0.02
NASDAQ : Health Technology
Prev Close 43.33
Open 43.62
Day Low/High 43.26 / 44.03
52 Wk Low/High 30.00 / 55.00
Volume 374.96K
Avg Volume 618.30K
Exchange NASDAQ
Shares Outstanding 41.30M
Market Cap 1.79B
P/E Ratio 241.44
Div & Yield N.A. (N.A)

Ratings Changes Coming on 5/10/2013

Upgrades: ABG, AI, AMCF, ARCP, CTL, MLU, SMG, STAN, SUPX, TSLA, ZOLT Downgrades: CUTR, FUN, LIOX, PCRX, PHX Initiations: CSTE

TheStreet Ratings Top 10 Rating Changes

TheStreet Ratings Top 10 Rating Changes

TheStreet Ratings released rating changes on 77 U.S. common stocks for week ending May 13, 2013. 45 stocks were upgraded and 32 stocks were downgraded by our stock model.

SALT 2013: The 5 Best Ideas of the Year Ahead

SALT 2013: The 5 Best Ideas of the Year Ahead

A panel of investment managers discuss their top picks at the Las Vegas event.

Pacira Pharmaceuticals Inc. Stock Downgraded (PCRX)

Pacira Pharmaceuticals Inc. Stock Downgraded (PCRX)

Pacira Pharmaceuticals (Nasdaq:PCRX) has been downgraded by TheStreet Ratings from from a hold to sell.

Analysis Of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost And Higher Likelihood Of Readmission

Analysis Of Postsurgical Pain Management Finds Opioid-Related Adverse Events Drive Longer Hospital Stays, Greater Cost And Higher Likelihood Of Readmission

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data from a large-scale analysis of a national database of patients from 380 hospitals in the United States who underwent 319,898 inpatient surgeries ...

Top Insider Trades: AGCO ECHO PCRX TWER

Top Insider Trades: AGCO ECHO PCRX TWER

The top 10 open-market insider purchases and sales filed at the SEC Monday.

Top Insider Trades: CHDN, PCRX, ULTA, PMBC

Top Insider Trades: CHDN, PCRX, ULTA, PMBC

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

'Mad Money' Lightning Round: Stick With Cummins, Sell Micron

'Mad Money' Lightning Round: Stick With Cummins, Sell Micron

Cramer said he's positive on CVS but doesn't believe in JC Penney.

Cramer's 'Mad Money' Recap: A Resting Bull Market

Cramer's 'Mad Money' Recap: A Resting Bull Market

Investors can still make money but they can't own stocks making all-time highs after a nine-day rally, Cramer said.

Pacira Pharmaceuticals Inc. Stock Upgraded (PCRX)

Pacira Pharmaceuticals Inc. Stock Upgraded (PCRX)

Pacira Pharmaceuticals (Nasdaq:PCRX) has been upgraded by TheStreet Ratings from a sell to hold.

Pacira Pharmaceuticals, Inc. To Present At The Barclays Global Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The Barclays Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare...

Pacira Pharmaceuticals, Inc. Announces Timing For 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s fourth quarter and year ended December 31, 2012, will be released before the market opens on Thursday, March 7,...

Pacira Pharmaceuticals, Inc. To Present At The Cowen And Company 33rd Annual Health Care Conference

Pacira Pharmaceuticals, Inc. To Present At The Cowen And Company 33rd Annual Health Care Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Cowen and Company 33 rd Annual ...

4 Stocks Rising on Unusual Volume

4 Stocks Rising on Unusual Volume

Unusual volume can also be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

Top Insider Trades: BAC LGND PCRX BDBD

Top Insider Trades: BAC LGND PCRX BDBD

The top 10 open-market insider purchases and sales filed at the SEC Friday.

Pacira Pharmaceuticals, Inc. Announces Pricing Of $110 Million Private Offering Of Convertible Senior Notes

Pacira Pharmaceuticals, Inc. Announces Pricing Of $110 Million Private Offering Of Convertible Senior Notes

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced that it has priced its private offering of $110 million in aggregate principal amount of its 3.

Pacira Pharmaceuticals, Inc. Announces Proposed Offering Of $100 Million Of Convertible Senior Notes

Pacira Pharmaceuticals, Inc. Announces Proposed Offering Of $100 Million Of Convertible Senior Notes

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) (the “Company”) today announced that it proposes to offer $100 million of aggregate principal amount of its convertible senior notes due 2019, subject to market...

New Publication Suggests Higher Opioid Use In The Postsurgical Setting May Be Linked To Extended Hospital Stay And Increased Cost Of Care

New Publication Suggests Higher Opioid Use In The Postsurgical Setting May Be Linked To Extended Hospital Stay And Increased Cost Of Care

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that the full findings from the regional health system analysis conducted by Barnabas Health to quantify the relationship between opioid use, total hospital...

Http://www.aratanatherapeutics.com/

Http://www.aratanatherapeutics.com/

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) and Aratana Therapeutics Inc.

New Data Demonstrate Reduction In Opioid Use, Hospital Cost And Length Of Stay With EXPAREL As The Foundation Of A Multimodal Regimen

New Data Demonstrate Reduction In Opioid Use, Hospital Cost And Length Of Stay With EXPAREL As The Foundation Of A Multimodal Regimen

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that results from the first IMPROVE study to complete its prospective Phase 4 clinical program were published in the online version of the Journal of...

Pacira Pharmaceuticals, Inc. To Present At The 24th Annual Piper Jaffray Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The 24th Annual Piper Jaffray Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the 24th Annual Piper Jaffray Healthcare ...

9 Hedge Fund Favorites With Barclays Buy Ratings Test 1

9 Hedge Fund Favorites With Barclays Buy Ratings Test 1

When an investment bank or other such specialized institution gives a stock a ⿿buy rating,⿝ they are advising investors they [...]

9 Hedge Fund Favorites With Barclays Buy Ratings

9 Hedge Fund Favorites With Barclays Buy Ratings

When an investment bank or other such specialized institution gives a stock a ⿿buy rating,⿝ they are advising investors they [...]

New Data Supporting Use Of EXPAREL Via Infiltration Into The Transversus Abdominis Plane Presented At 11th Annual American Society Of Regional Anesthesia And Pain Medicine Meeting

New Data Supporting Use Of EXPAREL Via Infiltration Into The Transversus Abdominis Plane Presented At 11th Annual American Society Of Regional Anesthesia And Pain Medicine Meeting

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the first data presentation supporting the use of EXPAREL ® (bupivacaine liposome injectable suspension) infiltrated into the transversus...

Pacira Pharmaceuticals, Inc. To Present At The Jefferies 2012 Global Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The Jefferies 2012 Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that David Stack, president and chief executive officer of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2012 Global Healthcare ...

Pacira Pharmaceuticals, Inc. Reports $4.6 Million In Third Quarter EXPAREL® Revenue And Full Third Quarter 2012 Financial Results

Pacira Pharmaceuticals, Inc. Reports $4.6 Million In Third Quarter EXPAREL® Revenue And Full Third Quarter 2012 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the quarter ended September 30, 2012 and provided updates on the commercial launch of EXPAREL® (bupivacaine...

Pacira Pharmaceuticals, Inc. Announces Timing For Third Quarter 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. Announces Timing For Third Quarter 2012 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc (NASDAQ: PCRX) today announced that financial results for the company's third quarter ended September 30, 2012, will be released before the market opens on Thursday, November 1, 2012.

Richard A. Baxter, M.D., Receives OR Excellence Award For Use Of EXPAREL®

Richard A. Baxter, M.D., Receives OR Excellence Award For Use Of EXPAREL®

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that prominent Seattle-based plastic surgeon Richard A.

Earnings Season Selloff

Today's decline could benefit the market by easing overbought technicals -- or it could be a warning.

EXPAREL® As The Foundation Of A Multimodal Regimen Achieves Statistical Significance In All Primary Endpoints, Including A 60 Percent Reduction In Length Of Hospital Stay

EXPAREL® As The Foundation Of A Multimodal Regimen Achieves Statistical Significance In All Primary Endpoints, Including A 60 Percent Reduction In Length Of Hospital Stay

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced topline results from the first completed IMPROVE study in its prospective Phase 4 clinical program.

TheStreet Quant Rating: C (Hold)